Systematic Approach for the Formulation and Optimization of Solid Lipid Nanoparticles of Efavirenz by High Pressure Homogenization Using Design of Experiments for Brain Targeting and Enhanced Bioavailability

Table 8

Stability study data for the formulation at initial, after 0.5, 1, 2, 3, and 6 months   are expressed as mean ± SD .

Temp; (°C)/RH (%)	Time; (months)	Appearance of; nanoparticulate; dispersion	Particle (nm)		Zeta; (mV)
	0	Transparent with; slight bluish
	0.5	No significant; change
	1	No significant; change
	2	No significant; change
	3	No significant; change
	6	No significant; change
	0	Transparent with; slight bluish
	0.5	No significant; change
	1	No significant; change
	2	No significant; change
	3	No significant; change
	6	No significant; change